Covestor LTD Harmony Biosciences Holdings, Inc. Transaction History

Covestor LTD

$160 Million
Q4 2024

A detailed history of Covestor LTD transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Covestor LTD holds 288 shares of HRMY stock, worth $11,226. This represents 0.01% of its overall portfolio holdings.

Number of Shares

288

Previous 298 3.36%

Holding current value

$11,226

Previous $12,000 16.67%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$31.86 - $41.49 $318 - $414	-10 Reduced 3.36%	288 $10,000
Q3 2024 Nov 01, 2024	SELL	$30.0 - $39.95 $2,070 - $2,756	-69 Reduced 18.8%	298 $12,000
Q2 2024 Aug 09, 2024	BUY	$28.81 - $33.01 $115 - $132	4 Added 1.1%	367 $11,000
Q1 2024 May 10, 2024	SELL	$29.93 - $35.06 $150,428 - $176,211	-5,026 Reduced 93.26%	363 $12,000
Q4 2023 Feb 09, 2024	BUY	$19.2 - $33.78 $14,112 - $24,828	735 Added 15.79%	5,389 $174,000
Q3 2023 Nov 13, 2023	BUY	$31.89 - $39.03 $6,920 - $8,469	217 Added 4.89%	4,654 $153,000
Q2 2023 Aug 11, 2023	BUY	$30.5 - $37.4 $58,072 - $71,209	1,904 Added 75.17%	4,437 $156,000
Q1 2023 May 15, 2023	BUY	$30.8 - $53.92 $29,999 - $52,518	974 Added 62.48%	2,533 $83,000
Q4 2022 Feb 13, 2023	SELL	$45.4 - $60.91 $3,949 - $5,299	-87 Reduced 5.29%	1,559 $85,000
Q3 2022 Nov 14, 2022	BUY	$42.06 - $55.45 $68,894 - $90,827	1,638 Added 20475.0%	1,646 $73,000
Q2 2022 Aug 10, 2022	SELL	$33.54 - $52.15 $134 - $208	-4 Reduced 33.33%	8 $0
Q1 2022 May 13, 2022	SELL	$33.14 - $51.13 $265 - $409	-8 Reduced 40.0%	12 $1,000
Q4 2021 Feb 10, 2022	BUY	$34.09 - $43.91 $681 - $878	20 New	20 $1,000

Others Institutions Holding HRMY

# of Institutions

254

Shares Held

45.6M

Call Options Held

111K

Put Options Held

46.9K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.31B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account